Alpha-synuclein (UniProt P37840; also known as NACP, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, Synuclein alpha-140) is encoded by the SNCA (also known as NACP, PARK1, PARK4) gene (Gene ID 6622) in human. Pathological aggregates are common features of many neurodegenerative diseases, such as tau neurofibrillary tangles (NFTs) in Alzheimer's disease (AD) and frontotemporal degeneration, and alpha-synuclein (alpha-syn or alphaS) Lewy bodies (LBs) in Parkinson's disease (PD) and dementia with LBs (DLB). Alpha-synuclein is a phospholipid-binding protein concentrated in presynaptic terminals where it promotes SNARE complex formation and modulates synaptic functions. Alpha-synuclein is the major component of pathologic inclusions that characterize PD, DLB, and multiple system atrophy (MSA). Research shows that alphaS exists not only as unfolded monomers, but in large part also as multimers, principally as ~60 kDa tetramers composed of four N-acetylated alphaS, that assume alpha-helical conformation and resist aggregation. PD-causing alphaS missense mutations are found to shift cellular alphaS from tetramers/multimers to monomers, indicating that decreased alpha-helical tetramers and increased unfolded monomers initiate pathogenesis. In addition, both casein kinase-1 (CK-1) and CK-2 can catalyze the phosphorylation of alphaS on Ser129, and Ser129-phosphorylated alphaS is found in alphaS inclusions.
Synonyms: Alpha-synuclein, NACP, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, Synuclein alpha-140
Application: Research CategoryNeuroscience
Other Notes: Concentration: Please refer to lot specific datasheet.